Secondary Immune Responses Memory B Cell Clone During
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ch. 43 the Immune System
Ch. 43 The Immune System 1 Essential Questions: How does our immunity arise? How does our immune system work? 2 Overview of immunity: Two kinds of defense: A. innate immunity present at time of birth before exposed to pathogens nonspecific responses, broad in range skin and mucous membranes internal cellular and chemical defenses that get through skin macrophages, phagocytic cells B. acquired immunity (adaptive immunity)develops after exposure to specific microbes, abnormal body cells, foreign substances or toxins highly specific lymphocytes produce antibodies or directly destroy cells 3 Overview of Immune System nonspecific Specific 4 I. Innate immunity Nonspecific defenses A. First line of defense: skin, mucous membranes skin protects against chemical, mechanical, pathogenic, UV light damage mucous membranes line digestive, respiratory, and genitourinary tracts prevent pathogens by trapping in mucus *breaks in skin or mucous membranes = entryway for pathogen 5 secretions of skin also protect against microbes sebaceous and sweat glands keep pH at 35 stomach also secretes HCl (Hepatitis A virus can get past this) produce antimicrobial proteins (lysozyme) ex. in tears http://vrc.belfastinstitute.ac.uk/resources/skin/skin.htm 6 B. Second line of defense internal cellular and chemical defenses (still nonspecific) phagocytes produce antimicrobial proteins and initiate inflammation (helps limit spread of microbes) bind to receptor sites on microbe, then engulfs microbe, which fused with lysosome nitric oxide and poisons in lysosome can poison microbe lysozyme and other enzymes degrade the microbe *some bacteria have capsule that prevents attachment *some bacteria are resistant to lysozyme macrophages 7 Cellular Innate defenses Tolllike receptor (TLR) recognize fragments of molecules characteristic of a set of pathogens [Ex. -
Stem Cells Cloning Prons & Cons
& Trans g ge in n n e s o l i s C Cloning and Transgenesis Kalodimou, Clon Transgen 2014, 3:3 ISSN: 2168-9849 DOI: 10.4172/2168-9849.1000127 Short Communication Open Access Stem Cells Cloning Prons & Cons Vasiliki E Kalodimou* Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece *Corresponding author: Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece, Tel: 0030-210-618-5; E-mail: [email protected] Rec date: May 16, 2014; Acc date: Jun 30, 2014; Pub date: July 2, 2014 Copyright: © 2014 Kalodimou VE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Stem Cell Cloning the target cell. In principle, this may be dangerous, because the gene therapy vector can potentially modify the activity of neighboring genes Over the last several decades, the ideas of both stem cell research (positively or negatively) in close proximity to the insertion site or and cloning have received significantly more attention than ever even inactivate host genes by integrating into them [6]. These before; currently there are 23 open/completed clinical trials, together phenomena may contribute to the malignant transformation of the with a great deal of controversy. This new advances in medical targeted cells, ultimately resulting in cancer. Another major limitation technology had provide scientific with a new view of potential to help of using adult stem cells is that it is relatively difficult to maintain the people suffering from various diseases as well as to help them recover stem cell state during ex vivo manipulations. -
Human Cloning: Must We Sacrifice Medical Research in the Name of a Total Ban?
S. HRG. 107–812 HUMAN CLONING: MUST WE SACRIFICE MEDICAL RESEARCH IN THE NAME OF A TOTAL BAN? HEARING BEFORE THE COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ONE HUNDRED SEVENTH CONGRESS SECOND SESSION FEBRUARY 5, 2002 Serial No. J–107–55 Printed for the use of the Committee on the Judiciary ( U.S. GOVERNMENT PRINTING OFFICE 83–684 PDF WASHINGTON : 2002 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC COMMITTEE ON THE JUDICIARY PATRICK J. LEAHY, Vermont, Chairman EDWARD M. KENNEDY, Massachusetts ORRIN G. HATCH, Utah JOSEPH R. BIDEN, JR., Delaware STROM THURMOND, South Carolina HERBERT KOHL, Wisconsin CHARLES E. GRASSLEY, Iowa DIANNE FEINSTEIN, California ARLEN SPECTER, Pennsylvania RUSSELL D. FEINGOLD, Wisconsin JON KYL, Arizona CHARLES E. SCHUMER, New York MIKE DEWINE, Ohio RICHARD J. DURBIN, Illinois JEFF SESSIONS, Alabama MARIA CANTWELL, Washington SAM BROWNBACK, Kansas JOHN EDWARDS, North Carolina MITCH MCCONNELL, Kentucky BRUCE A. COHEN, Majority Chief Counsel and Staff Director SHARON PROST, Minority Chief Counsel MAKAN DELRAHIM, Minority Staff Director (II) VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00002 Fmt 5904 Sfmt 5904 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC C O N T E N T S STATEMENTS OF COMMITTEE MEMBERS Page Brownback, Hon. -
Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs Using Somatic Cell Nuclear Transfer Sharon J
& Trans Harrison et al., Clon Transgen 2015, 4:2 g ge in n n e DOI: 10.4172/2168-9849.1000136 s o l i s C Cloning & Transgenesis ISSN: 2168-9849 Research Article Open Access Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs using Somatic Cell Nuclear Transfer Sharon J. Harrison, Luke F.S. Beebe, Ivan Vassiliev, Stephen M. McIlfatrick and Mark B. Nottle* Reproductive Biotechnology Group, Centre for Stem Cell Research, Robinson Institute School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, 5005, Australia Abstract We have previously demonstrated that the use of porcine mesenchymal stem cells (MSCs) isolated from the bone marrow can increase the proportion of somatic cell nuclear transfer (SCNT) embryos that develop to the blastocyst stage compared with adult fibroblasts obtained from the same animal. The aim of the present study was to determine if MSCs are also present in primary cultures of adult fibroblasts which are commonly used for cloning live animals. To do this we chose a primary culture of adult fibroblasts that we had previously used to clone pigs. Single cell clones were isolated using low-density plating. After seven days of culture 63% of colonies displayed typical fibroblast morphology, while the remainder appeared cobblestone-like in appearance. Two of the 57 clones that displayed fibroblast morphology differentiated into adipocytes but not chondrocytes or osteocytes (uni-potent clones). Three of the 33 cobblestone-like clones differentiated into chondrocytes only, while 3 differentiated into adipocytes and chondrocytes but not osteocytes (bi-potent clones). One of the bi-potent cobblestone-like clones was then used for SCNT and in vitro development compared with a fibroblast-like clone which did not differentiate. -
The RAG Recombinase Dictates Functional Heterogeneity and Cellular Fitness in Natural Killer Cells
The RAG Recombinase Dictates Functional Heterogeneity and Cellular Fitness in Natural Killer Cells Jenny M. Karo,1 David G. Schatz,2 and Joseph C. Sun1,* 1Immunology Program and Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 2Department of Immunobiology and the Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.cell.2014.08.026 SUMMARY completely absent (Mombaerts et al., 1992; Shinkai et al., 1992). There is as yet no evidence that RAG plays a physiological The emergence of recombination-activating genes role in any cell type other than B and T lymphocytes or in any pro- (RAGs) in jawed vertebrates endowed adaptive cess other than V(D)J recombination. immune cells with the ability to assemble a diverse Although NK cells have long been classified as a component set of antigen receptor genes. In contrast, innate of the innate immune system, recent evidence suggests that lymphocytes, such as natural killer (NK) cells, are this cell type possesses traits attributable to adaptive immunity not believed to require RAGs. Here, we report that (Sun and Lanier, 2011). These characteristics include ‘‘educa- tion’’ mechanisms to ensure self-tolerance during NK cell devel- NK cells unable to express RAGs or RAG endonu- opment and clonal-like expansion of antigen-specific NK clease activity during ontogeny exhibit a cell-intrinsic cells during viral infection, followed by the ability to generate hyperresponsiveness but a diminished capacity long-lived ‘‘memory’’ NK cells. -
LECTURE 05 Acquired Immunity and Clonal Selection
LECTURE: 05 Title: ACQUIRED "ADAPTIVE" IMMUNITY & CLONAL SELECTION THEROY LEARNING OBJECTIVES: The student should be able to: • Recognize that, acquired or adaptive immunity is a specific immunity. • Explain the mechanism of development of the specific immunity. • Enumerate the components of the specific immunity such as A. Primary immune response. B. Secondary immune response • Explain the different phases that are included in the primary and secondary immune responses such as: A. The induction phase. B. Exponential phase. C. Steady phase. D. Decline phase. • Compare between the phases of the primary and secondary immune responses. • Determine the type of the immunoglobulins involved in each phase. • Determine which immunoglobulin is induced first and, that last longer. • Enumerate the characteristics of the specific immunity such as: A. The ability to distinguish self from non-self. B. Specificity. C. Immunological memory. • Explain naturally and artificially acquired immunity (passive, and active). • Explain the two interrelated and independent mechanisms of the specific immune response such as : A. Humoral immunity. B. Cell-mediated (cellular) immunity. • Recognize that, the specific immunity is not always protective, for example; sometimes it causes allergies (hay fever), or it may be directed against one of the body’s own constituents, resulting in autoimmunity (thyroditis). LECTURE REFRENCE: 1. TEXTBOOK: ROITT, BROSTOFF, MALE IMMUNOLOGY. 6th edition. Chapter 2. pp. 15-31 2. TEXTBOOK: ABUL K. ABBAS. ANDREW H. LICHTMAN. CELLULAR AND MOLECULAR IMMUNOLOGY. 5TH EDITION. Chapter 1. pg 3-12. 1 ACQUIRED (SPECIFIC) IMMUNITY INTRODUCTION Adaptive immunity is created after an interaction of lymphocytes with particular foreign substances which are recognized specifically by those lymphocytes. -
Med-Pathway Zoom Workshop
MCAT Immunology Dr. Phillip Carpenter medpathwaymcat Med-pathway AAMC MCAT Content Outline: Immunology Category 1A: Structure/Function of Proteins/AA Immune System Category 3B: Organ Systems Innate vs. Adaptive Immunity T and B Lymphocytes Macrophages & Phagocytes Tissue-Bone marrow, Spleen, Thymus, Lymph nodes Antigen and Antibody Antigen Presentation Clonal Selection Antigen-Antibody recognition Structure of antibody molecule Self vs. Non-self, Autoimmune Diseases Major Histocompatibility Complex Lab Techniques: ELISA & Western Blotting Hematopoiesis Creates Immune Cells Self vs. Non-self Innate vs Adaptive Innate Immunity Physical Barriers: Skin, mucous membranes, pH Inflammatory mediators: Complement, Cytokines, Prostaglandins Cellular Components: Phagocytes-Neutrophils, Eosinophils, Basophils, Mast Cells Antigen Presenting Cells-Monocytes, Macrophages, Dendritic Cells Adaptive (Acquired) Immunity Composed of B and T lymphocytes: Activated by Innate Immunity B cells: Express B cell receptor and secrete antibodies as plasma cells T cells: Mature in thymus, express TCR surface receptor; Activated by Antigen Presenting Cells (APCs) Direct Immune response (The Ringleaders of immune system) Major Lymphoid Organs TYPE SITE FUNCTION Fetal production of Liver 1° lymphoid cells Hematopoietic production of 1° Bone marrow myeloid and lymphoid cells Receives bone marrow T 1° Thymus cells; site where self is selected from non-self Lymph nodes 2° Sites of antigen activation Spleen of lymphocytes; clearance Macrophages (Sentinel Cells) Pattern Recognition -
Replication Study: Wnt Activity Defines Colon Cancer Stem Cells and Is
REPLICATION STUDY Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment Anthony Essex1, Javier Pineda1, Grishma Acharya2, Hong Xin2, James Evans1, Reproducibility Project: Cancer Biology* 1PhenoVista Biosciences, San Diego, United States; 2Explora BioLabs Inc, San Diego, United States Abstract As part of the Reproducibility Project: Cancer Biology we published a Registered Report (Evans et al., 2015), that described how we intended to replicate selected experiments from the paper ‘Wnt activity defines colon cancer stem cells and is regulated by the microenvironment’ (Vermeulen et al., 2010). Here, we report the results. Using three independent primary spheroidal colon cancer cultures that expressed a Wnt reporter construct we observed high Wnt activity was associated with the cell surface markers CD133, CD166, and CD29, but not CD24 and CD44, while the original study found all five markers were correlated with high Wnt activity (Figure 2F; Vermeulen et al., 2010). Clonogenicity was highest in cells with high Wnt activity and clonogenic potential of cells with low Wnt activity were increased by myofibroblast-secreted factors, including HGF. While the effects were in the same direction as the original study (Figure 6D; Vermeulen et al., 2010) whether statistical significance was reached among the different conditions varied. When tested in vivo, we did not find a difference in tumorigenicity between high and low Wnt activity, while the original study found cells with high Wnt activity were more effective in inducing tumors (Figure 7E; Vermeulen et al., 2010). Tumorigenicity, however, was increased with *For correspondence: myofibroblast-secreted factors, which was in the same direction as the original study (Figure 7E; [email protected]; Vermeulen et al., 2010), but not statistically significant. -
Targeting Chemoresistant Colorectal Cancer Via Systemic Administration of a BMP7 Variant
Oncogene (2020) 39:987–1003 https://doi.org/10.1038/s41388-019-1047-4 ARTICLE Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant 1 1 1 1 1 Veronica Veschi ● Laura R. Mangiapane ● Annalisa Nicotra ● Simone Di Franco ● Emanuela Scavo ● 1 1 2 1 1 1 Tiziana Apuzzo ● Davide S. Sardina ● Micol Fiori ● Antonina Benfante ● Maria L. Colorito ● Gianfranco Cocorullo ● 3,4 1 5 5 6 Felice Giuliante ● Calogero Cipolla ● Giuseppe Pistone ● Maria Rita Bongiorno ● Aroldo Rizzo ● 7 7 7 7 5 3,4 Courtney M. Tate ● Xiaohua Wu ● Scott Rowlinson ● Louis F. Stancato ● Matilde Todaro ● Ruggero De Maria ● Giorgio Stassi1 Received: 10 April 2019 / Revised: 23 September 2019 / Accepted: 25 September 2019 / Published online: 7 October 2019 © The Author(s) 2019. This article is published with open access Abstract Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced 1234567890();,: 1234567890();,: sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy- resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors. -
REVIEW Multiple Myeloma: the Cells of Origin – a Two-Way Street
Leukemia (1998) 12, 121–127 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 REVIEW Multiple myeloma: the cells of origin – A two-way street JR Berenson, RA Vescio and J Said West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA, USA Multiple myeloma results from an interplay between the mono- earlier precursor cells may be responsible for the proliferation clonal malignant plasma cells and supporting nonmalignant of the malignant population. The presence of a circulating cells in the bone marrow. Recent studies suggest that the final transforming event in this B cell disorder occurs at a late stage tumor component without obvious plasma cell morphology of B cell differentiation based on the characteristics of the also suggests that less mature lymphocytes may be part of the immunoglobulin genes expressed by the malignant clone as clone as well, which could explain the dissemination of the well as surface markers present on the tumor cells. Recently, disease throughout the bone marrow.4 In addition, evidence an increasing pathogenic role in this malignancy by the nonma- for tumor cells at even earlier stages of hematopoietic differen- lignant cells in the bone marrow has been suggested by several tiation came from studies showing the high rate of acute non- studies. Specific infection of these supporting cells by the lymphoblastic leukemia in these patients and the presence of recently identified Kaposi’s sarcoma-associated herpes virus 5,6 (KSHV) suggests a novel mechanism by which this nonmalig- non-lymphoid surface markers on malignant plasma cells. A nant population may lead to the development of this B cell variety of molecular biological techniques have subsequently malignancy and support its growth. -
T Cell Clones +CD8 Functional Diversity in Melanoma-Specific
Trogocytosis Is a Gateway to Characterize Functional Diversity in Melanoma-Specific CD8+ T Cell Clones This information is current as Ronny Uzana, Galit Eisenberg, Yael Sagi, Shoshana of October 2, 2021. Frankenburg, Sharon Merims, Ninette Amariglio, Eitan Yefenof, Tamar Peretz, Arthur Machlenkin and Michal Lotem J Immunol 2012; 188:632-640; Prepublished online 7 December 2011; doi: 10.4049/jimmunol.1101429 Downloaded from http://www.jimmunol.org/content/188/2/632 Supplementary http://www.jimmunol.org/content/suppl/2011/12/07/jimmunol.110142 http://www.jimmunol.org/ Material 9.DC1 References This article cites 50 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/188/2/632.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Trogocytosis Is a Gateway to Characterize Functional Diversity in Melanoma-Specific CD8+ T Cell Clones Ronny Uzana,* Galit Eisenberg,* Yael Sagi,† Shoshana Frankenburg,* Sharon Merims,* Ninette Amariglio,‡ Eitan Yefenof,x Tamar Peretz,* Arthur Machlenkin,*,1 and Michal Lotem*,1 Trogocytosis, the transfer of membrane patches from target to immune effector cells, is a signature of tumor–T cell interaction. -
How Many Different Clonotypes Do Immune Repertoires Contain?
How many different clonotypes do immune repertoires contain? Thierry Mora and Aleksandra M. Walczak Laboratoire de physique de l'Ecole´ normale sup´erieure (PSL University), CNRS, Sorbonne Universit´e,and Universit´ede Paris, 75005 Paris, France Immune repertoires rely on diversity of T-cell and B-cell receptors to protect us against foreign threats. The ability to recognize a wide variety of pathogens is linked to the number of different clonotypes expressed by an individual. Out of the estimated ∼ 1012 different B and T cells in humans, how many of them express distinct receptors? We review current and past estimates for these numbers. We point out a fundamental limitation of current methods, which ignore the tail of small clones in the distribution of clone sizes. We show that this tail strongly affects the total number of clones, but it is impractical to access experimentally. We propose that combining statistical models with mechanistic models of lymphocyte clonal dynamics offers possible new strategies for estimating the number of clones. I. INTRODUCTION dent [9, 10]. The total number of different αβ pairs that the generation machinery can produce is much greater The diversity of immune repertoires plays an impor- than the total number of receptors in the whole human tant role in the host's ability to recognize and control population [9, 11, 12]. Thus, each person harbors only a wide range of pathogens. While actual recognition of a small fraction of the potential diversity of receptors. an antigen depends on having a relatively specific T-cell To estimate the number of distinct receptors, we need to or B-cell receptor (TCR or BCR), multiple experimen- count them.